Tocilizumab (Acterma) is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients. Explore the live graph.
Mechanistic analysis of Tocilizumab
LACTATE DEHYDROGENASE
Mechanistic analysis of Acalabrutinib (Calquence)
Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More
Administration of vitamin D could help fight COVID-19
Vitamin D supplementation has been shown to protect against SARS-COV-2 infection, and could be particularly helpful for patients that exhibit shortage of vitamin D (e.g. seniors, immunocompromised patients) leading to complications such as cardiovascular comorbidities. This graph explains the mechanism of action of vitamin D in COVID-19 via key genes implicated. Explore the live graph.
Possibly implicated genes in SARS-CoV-2-mediated blood vessel disease
In addition to respiratory symptoms, novel findings have shown vascular complications in a series of patients with COVID-19, suggesting that COVID-19 is more to a respiratory infection caused by SARS-CoV-2. This graph illustrates some of the possible mechanisms (genes) by which these effects of SARS-CoV-2 may be mediated. Explore the live graph.
Lopinavir/Ritonavir mechanism of action analysis in COVID-19
Lopinavir/Ritonavir (Kaletra) is a combination of the antivirals Lopinavir and Ritonavir, that were originally designed to inhibit HIV from replicating by binding to the protease. Similarly, it has been postulated that the drug could also bind to the protease of SARS-CoV-2. The drug is currently being tested for the treatment of COVID-19. Explore the live … Read More